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Background
Patch testing (PT) is a part of tools used for the etiolo-
gical diagnosis of a cutaneous adverse reaction (CADR).
Positivity of PT is observed in above 30 to 50 % of
explored cases. Recommended procedure is based on
dilution in petroleum or in water at 30 % for the finished
product or at 10 % for the active ingredient. Chemotech-
nique laboratory supplies, in the form of ready for use
syringes, around 30 active ingredients. Other medicines
must be thus prepared by a hospital pharmacy, according
to the strict protocol. Thus, preparations are not available
in all the test centers and some patients can not be
explored. We led a forward-looking study comparing the
extemporaneous tests, easily practicable, compared with
the recommended procedures. Patients and methods The
programmed tests were performed at the same time with
Chemotechnique products or pharmaceutical prepara-
tions and with tablets brought by the patients, crushed
manually with a pestle in order to transform in powder
and then mixed in petroleum. The used chambers were
Q or IQ chambers ( Chemotechnique ) and the readings
realized at 48 and 96 hours.
Results
70 patients (25 men/ 45 women) were included. Seven
were tested with 2 different molecules, thus 77 double
tests were performed. Tested substances included usual
CADR inducers such as allopurinol (n=9), amoxicillin
(n=25), tetrazepam (n=7), pristinamycin (n=10) and 16
others molecules. CADR tested included maculopapular
rash (MPR; n=27), Drug Reaction with Eosinophilia and
Systemic Symptoms (DRESS; n=9), Acute Generalized
Exanthematous Pustulosis (AGEP; n=12), Fixed Drug
Reaction (FDE; n=5), Linear IgA Dermatosis (n=2),
Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
(n=15), erytroderma (n=3) and eczematous rash (n=2).
All the tests were coherent: 20 positive tests and 57
negative with the 2 techniques. As usually observed in
literature with recommended patch testing, the positive
tests were observed preferentially with some ingredients
(amoxicillin, tetrazepam, pristinamycin) and conversely
there was no positive tests with allopurinol, ibuprofen
and piroxicam. As well, patch testing was more fre-
quently positive with some kinds of CADR (AGEP and
MPR), confirming reliability of the tests.
Conclusion
For the patients that could not consult easily in centers
having access to the pharmaceutical preparations but
nevertheless expert in CADR, the extemporaneous pre-
parations constitute a possible alternative.
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